220 related articles for article (PubMed ID: 28456864)
1. A randomized, controlled clinical trial to evaluate the immunogenicity of a PreS/S hepatitis B vaccine Sci-B-Vac™, as compared to Engerix B
Elhanan E; Boaz M; Schwartz I; Schwartz D; Chernin G; Soetendorp H; Gal Oz A; Agbaria A; Weinstein T
Clin Exp Nephrol; 2018 Feb; 22(1):151-158. PubMed ID: 28456864
[TBL] [Abstract][Full Text] [Related]
2. Sci-B-VacTM Vs ENGERIX-B Vaccines for Hepatitis B Virus in Patients with Inflammatory Bowel Diseases: A Randomised Controlled Trial.
Etzion O; Novack V; Perl Y; Abel O; Schwartz D; Munteanu D; Abufreha N; Ben-Yaakov G; Maoz ED; Moshaklo A; Dizingf V; Fich A
J Crohns Colitis; 2016 Aug; 10(8):905-12. PubMed ID: 26928962
[TBL] [Abstract][Full Text] [Related]
3. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B Virus Revaccination With Standard Versus Pre-S Vaccine in Previously Immunized Patients With Celiac Disease.
Heshin-Bekenstein M; Turner D; Shamir R; Bar-Meir M; Dagan R; Zevit N; Silbermintz A
J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):400-3. PubMed ID: 25988560
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of Sci-B-Vac (a Third-Generation Hepatitis B Vaccine) in HIV-Positive Adults.
Alon D; Stein GY; Hadas-Golan V; Tau L; Brosh T; Turner D
Isr Med Assoc J; 2017 Mar; 19(3):143-146. PubMed ID: 28457089
[TBL] [Abstract][Full Text] [Related]
6. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D; Roggendorf H; Roggendorf M
Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
[TBL] [Abstract][Full Text] [Related]
7. Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults.
Hernández-Bernal F; Aguilar-Betancourt A; Aljovin V; Arias G; Valenzuela C; de Alejo KP; Hernández K; Oquendo O; Figueredo N; Figueroa N; Musacchio A; Véliz G; García E; Mollineda AD; Juvier AI; Trujillo J; Delahanty A; Ortega D; Cinza Z; González VL
Hum Vaccin; 2011 Oct; 7(10):1026-36. PubMed ID: 21941089
[TBL] [Abstract][Full Text] [Related]
8. Extra-high-dose hepatitis B vaccination does not confer longer serological protection in peritoneal dialysis patients: a randomized controlled trial.
Chow KM; Lo SH; Szeto CC; Yuen SK; Wong KS; Kwan BC; Leung CB; Li PK
Nephrol Dial Transplant; 2010 Jul; 25(7):2303-9. PubMed ID: 20185409
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients.
Tung J; Carlisle E; Smieja M; Kim PT; Lee CH
Am J Kidney Dis; 2010 Oct; 56(4):713-9. PubMed ID: 20630640
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial.
Vesikari T; Langley JM; Segall N; Ward BJ; Cooper C; Poliquin G; Smith B; Gantt S; McElhaney JE; Dionne M; van Damme P; Leroux-Roels I; Leroux-Roels G; Machluf N; Spaans JN; Yassin-Rajkumar B; Anderson DE; Popovic V; Diaz-Mitoma F;
Lancet Infect Dis; 2021 Sep; 21(9):1271-1281. PubMed ID: 33989539
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine.
Kuan RK; Janssen R; Heyward W; Bennett S; Nordyke R
Vaccine; 2013 Aug; 31(37):4024-32. PubMed ID: 23707166
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
[TBL] [Abstract][Full Text] [Related]
13. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination.
Barraclough KA; Wiggins KJ; Hawley CM; van Eps CL; Mudge DW; Johnson DW; Whitby M; Carpenter S; Playford EG
Am J Kidney Dis; 2009 Jul; 54(1):95-103. PubMed ID: 19481320
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunogenicity of 2 recombinant hepatitis B vaccines (GeneVac-B and Engerix-B) in adult patients with chronic renal failure.
Rajapurkar MM; Gang S; Dabhi M; Kulkarni PS
J Nephrol; 2007; 20(5):596-601. PubMed ID: 17918146
[TBL] [Abstract][Full Text] [Related]
15. Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: A phase 3 randomized clinical trial.
Diaz-Mitoma F; Popovic V; Spaans JN
Vaccine; 2021 Jun; 39(29):3892-3899. PubMed ID: 34116873
[TBL] [Abstract][Full Text] [Related]
16. Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China.
Zhu F; Deckx H; Roten R; Michiels B; Sarnecki M
Pediatr Infect Dis J; 2017 Jan; 36(1):94-101. PubMed ID: 27753794
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults.
Jackson S; Lentino J; Kopp J; Murray L; Ellison W; Rhee M; Shockey G; Akella L; Erby K; Heyward WL; Janssen RS;
Vaccine; 2018 Jan; 36(5):668-674. PubMed ID: 29289383
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.
Tong NK; Beran J; Kee SA; Miguel JL; Sánchez C; Bayas JM; Vilella A; de Juanes JR; Arrazola P; Calbo-Torrecillas F; de Novales EL; Hamtiaux V; Lievens M; Stoffel M
Kidney Int; 2005 Nov; 68(5):2298-303. PubMed ID: 16221232
[TBL] [Abstract][Full Text] [Related]
19. Antibody response to hepatitis B vaccine in end-stage renal disease patients.
Chow KM; Law MC; Leung CB; Szeto CC; Li PK
Nephron Clin Pract; 2006; 103(3):c89-93. PubMed ID: 16534237
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules.
McNulty CA; Bowen JK; Williams AJ
Vaccine; 2005 Jul; 23(32):4142-7. PubMed ID: 15913854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
